Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology

Roche and Foundation Medicine, Inc. today announced they have entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI ’s common stock not already owned by Roche and its affiliates at a price of US$ 137.00 per share in cash.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news